"Further, when CART cells were treated with IL-4, they developed signs of exhaustion, but when CART cells were treated with an IL-4 monoclonal antibody, they showed improved antitumor efficacy and reduced signs of exhaustion in preclinical models."

#immunology #immunotherapy #CARTCells #Preprint

https://www.biorxiv.org/content/10.1101/2023.09.28.560046v1